REFERENCES
1. Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol . Feb 2012;22(1):1-14. doi:10.1007/s10165-011-0508-6
2. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med . Mar 8 2001;344(10):732-8. doi:10.1056/NEJM200103083441005
3. Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol . Jan 2011;23(1):57-66. doi:10.1097/BOR.0b013e3283418057
4. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol . Sep 2012;25(9):1181-92. doi:10.1038/modpathol.2012.72
5. Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease.Ann Rheum Dis . Jan 2015;74(1):14-8. doi:10.1136/annrheumdis-2013-204907
6. Bjornsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology . Jun 2007;45(6):1547-54. doi:10.1002/hep.21685
7. Kamisawa T, Nakazawa T, Tazuma S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci . Jan 2019;26(1):9-42. doi:10.1002/jhbp.596
8. Tanaka A, Tazuma S, Okazaki K, et al. Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis.Clin Gastroenterol Hepatol . Jun 2017;15(6):920-926 e3. doi:10.1016/j.cgh.2016.12.038
9. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.Gastroenterology . Mar 2008;134(3):706-15. doi:10.1053/j.gastro.2007.12.009
10. Lin J, Cummings OW, Greenson JK, et al. IgG4-related sclerosing cholangitis in the absence of autoimmune pancreatitis mimicking extrahepatic cholangiocarcinoma. Scand J Gastroenterol . Apr 2015;50(4):447-53. doi:10.3109/00365521.2014.962603
11. Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.World J Gastroenterol . Feb 1 2004;10(3):427-32. doi:10.3748/wjg.v10.i3.427
12. Naitoh I, Kamisawa T, Tanaka A, et al. Clinical characteristics of immunoglobulin IgG4-related sclerosing cholangitis: Comparison of cases with and without autoimmune pancreatitis in a large cohort. Dig Liver Dis . Oct 2021;53(10):1308-1314. doi:10.1016/j.dld.2021.02.009
13. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med . Feb 9 2012;366(6):539-51. doi:10.1056/NEJMra1104650
14. Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol . Jan 2011;23(1):119-24. doi:10.1097/BOR.0b013e3283412fd4
15. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease.Lancet . Apr 11 2015;385(9976):1460-71. doi:10.1016/S0140-6736(14)60720-0
16. Joshi D, Webster GJM. IgG4 Related Sclerosing Cholangitis. Adv Hepatol . 2014/11/10 2014;2014:632320. doi:10.1155/2014/632320
17. Drazilova S, Veseliny E, Lenartova PD, et al. IgG4-Related Sclerosing Cholangitis: Rarely Diagnosed, but not a Rare Disease.Can J Gastroenterol Hepatol . 2021;2021:1959832. doi:10.1155/2021/1959832
18. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut . Nov 2009;58(11):1504-7. doi:10.1136/gut.2008.172908
19. Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol . Jan 2011;23(1):67-71. doi:10.1097/BOR.0b013e328341a240
20. Xiao J, Li G, Yang G, Jia C, Li B. Case report: A female case of isolated IgG4-related sclerosing cholangitis mimicking cholangiocarcinoma. Medicine (Baltimore) . Apr 2017;96(16):e6542. doi:10.1097/MD.0000000000006542
Table 1. Comparison of laboratory findings among the time of initial presentation, at the end of steroid therapy and after three years